Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Ipsen ( (FR:IPN) ).
Ipsen reported phase II data for its first‑in‑class recombinant neuro‑inhibitor corabotase in patients with moderate to severe glabellar lines, showing a rapid onset of action, superior peak effect to placebo and stronger wrinkle reduction than Dysport at key time points. The 50 ng dose delivered a sustained clinical response in 60.8% of patients at week 24, with 82.8% declaring themselves satisfied or very satisfied, and demonstrated a safety profile comparable to Dysport and placebo.
Corabotase’s prolonged duration of effect and favorable tolerability profile position it as a potential new competitor in the aesthetics market, extending Ipsen’s neuromuscular franchise beyond Dysport. The company has selected the 50 ng dose for phase III development in the LAURITE program and is running the phase I/II LANTIC study across glabellar lines, forehead lines and crow’s feet, signaling a strategic push to capture share in upper‑face aesthetic treatments.
The most recent analyst rating on (FR:IPN) stock is a Hold with a EUR170.00 price target. To see the full list of analyst forecasts on Ipsen stock, see the FR:IPN Stock Forecast page.
More about Ipsen
Ipsen is a global biopharmaceutical group focused on developing innovative medicines across oncology, rare diseases and neurosciences. The company leverages both internal research and external partnerships to build its R&D portfolio, and is expanding into aesthetics with recombinant neuro‑inhibitor technologies such as corabotase targeting upper‑face wrinkle indications.
Average Trading Volume: 114,473
Technical Sentiment Signal: Buy
Current Market Cap: €13.73B
See more insights into IPN stock on TipRanks’ Stock Analysis page.